Development and in vitro evaluation of pH-independent release matrix tablet of weakly acidic drug valsartan using quality by design tools

Abstract

The main objective of this study was the development of pH-independent controlled release valsartan matrix tablet in Quality by design (QbD) framework. The quality target product profile (QTPP), critical quality attributes (CQAs) and critical material attributes (CMAs) were defined by science and risk-based methodologies. Potential risk factors were identified with Fishbone diagram. Following, CMAs were further investigated with a semi-quantitative risk assessment method, which has been revised with mitigated risks after development and optimization studies. According to defined critical material attributes, which one of them was determined to be the dissolution, formulation optimization study was performed by using a statistical design of experiment. Formulation variables have been identified and fixed first with a 'One factor at a time (OFAT)' approach. After OFAT studies, a statistical experimental design was conducted with the most critical material attributes. Statistical design space and mathematical prediction equations have been developed for dissolution and hardness, which is important to predict drug dissolution behavior. In conclusion, a pH-independent release has been achieved for weakly acidic drug valsartan with a deeper understanding of drug product quality, with the science and risk-based approaches of QbD tools.

Harmonizing Design, Risk, Metrology and Standardization in Managing the Development of Drugs using Nanotechnology

“…The Process Analytical Technology Framework (PAT), supported by the International Conference on Harmonization (ICH) provided the pharmaceutical industry sound practice over the years that has consolidated chemical, physical, microbiological, mathematical, risk assessment and regulatory insights to provide a navigation tool for strategic development and implementation of manufacturing and quality assurance. The salient features included are: a risk management and quality systems to maintain the quality of the system, access to latest technologies and developments, reviews and inspection activities, regulatory reflections and, health and safety (US FDA 2004;Orzechowski et al 2018;Saydam and Takka 2018).…”

Development, optimization and pharmacokinetic evaluation of biphasic extended-release osmotic drug delivery system of trospium chloride for promising application in treatment of overactive bladder

“…The ANOVA analysis revealed that at 20th hour polyethylene oxide was found to be the most influencing factor. An increase in the level of polyethylene oxide decreases drug release while cellulose acetate and polyethylene glycol are having no such effect [36].…”

Amalgamation of QbD and Alcohol Induced Dose Dumping Studies on Diltiazem Hydrochloride Modified Release Tablets

“…[21][22][23] Post-compressional Parameters All factorial batches of the tablets were evaluated for official and unofficial test as per pharmacopoeia for weight variation, thickness, hardness and friability. 22,24,25 No Colour, shape and appearance are not directly linked to safety and efficacy. Therefore, they are not critical.…”